Technology
Health
Medical

Genmab

$17.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.00 (0.03%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Genmab and other stocks, options, ETFs, and crypto commission-free!

About

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer. Read More Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark. GMXAY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).

Employees
377
Headquarters
Copenhagen, Capital Region
Founded
1999
Market Cap
2.11B
Price-Earnings Ratio
10.13
Dividend Yield
0.00
Average Volume
52.33K
High Today
$17.25
Low Today
$17.17
Open Price
$17.21
Volume
24.33K
52 Week High
$20.88
52 Week Low
$12.10

Collections

Technology
Health
Medical
Biotechnology
Therapy
Cancer Prevention
2013 IPO
Europe (Non-UK)

News

Yahoo FinanceMay 13

Why Earnings Season Could Be Great for Genmab

Investors are always looking for stocks that are poised to beat at earnings season and Genmab A/S GNMSF may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Genmab is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator ...

4
Seeking AlphaMay 12

Genmab A/S CEO Jan van de Winkel on Q1 2019 Results - Earnings Call Transcript

Genmab A/S (OTCPK:GNMSF) Q1 2019 Earnings Conference Call May 8, 2019 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, CEO and President David Eatwell - EVP and CFO Conference Call Participants Wimal Kapadia - Sanford C. Bernstein & Co. Thomas Bowers - Danske Bank Sachin Jain - Bank of America Merrill Lynch James Quigley - JPMorgan Chase & Co. Michael Novod - Nordea Peter Welford - Jefferies Jack Scannell - UBS Graig Suvannavejh - Goldman Sachs Operator Good afternoon, ladies a...

1
Markets InsiderMay 8

Genmab Announces Financial Results for the First Quarter of 2019

May 8, 2019; Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2019 Highlights Regulatory applications for daratumumab in combination with lenalidomide and dexamethasone based on the MAIA study in frontline multiple myeloma submitted in U.S. and Europe Regulatory applications for daratumumab in combination with bortezomib, thalidomide and dexamethasone based on the CASSIOPEIA study in frontline multiple myeloma submitted in U.S. and Europe Positive topline results from Phase III...

10
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.